The hallucinogenic herb Salvia divinorum and its active ingredient salvinorin A reduce inflammation-induced hypermotility in mice

被引:33
作者
Capasso, R. [1 ]
Borrelli, F. [1 ]
Zjawiony, J. [2 ,3 ]
Kutrzeba, L. [2 ]
Aviello, G. [1 ]
Sarnelli, G. [4 ]
Capasso, F. [1 ]
Izzo, A. A. [1 ]
机构
[1] Univ Naples Federico 2, Dept Expt Pharmacol, I-80131 Naples, Italy
[2] Univ Mississippi, Dept Pharmacognosy, University, MS 38677 USA
[3] Res Inst Pharmacuet Sci, Natl Ctr Nat Prod Res, Sch Pharm, University, MS 38677 USA
[4] Univ Naples Federico 2, Dept Clin & Expt Med, Gastroenterol Unit, Naples, Italy
关键词
inflammation; intestinal motility; kappa-opioid receptors; myenteric plexus; salvinorin A;
D O I
10.1111/j.1365-2982.2007.00994.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
The hallucinogenic plant Salvia divinorum has been used for medical treatments of gastrointestinal disorders. Here, we evaluated the effect of a standardized extract from the leaves of Salvia divinorum (SDE) and of its active ingredient salvinorin A on motility in vivo, both in physiological states and during croton oil-induced intestinal inflammation. SDE (1-100 mg kg(-1)) significantly inhibited motility only in inflamed, but not in control, mice. In control mice, salvinorin A (0.01-10 mg kg(-1)) significantly inhibited motility only at the highest doses tested (3 and 10 mg kg(-1)) and this effect was not counteracted by naloxone or by the kappa-opioid receptor (KOR) antagonist nor-binaltorphimine. Inflammation significantly increased the potency of salvinorin A (but not of the KOR agonist U-50488) in reducing motility. The inhibitory effects of both salvinorin A and U-50488 in inflamed mice were counteracted by naloxone or by nor-binaltorphimine. We conclude that salvinorin A may reduce motility through activation of different targets. In physiological states, salvinorin A, at high doses, inhibited motility through a non-KOR mediated mechanism. Gut inflammation increased the potency of salvinorin A; this effect was mediated by KOR, but it was not shared by U-50488, thus suggesting that salvinorin A may have target(s) other than KOR in the inflamed gut.
引用
收藏
页码:142 / 148
页数:7
相关论文
共 24 条
[1]
KAPPA-OPIATE AGONIST-INDUCED INHIBITION OF GASTROINTESTINAL TRANSIT IN DIFFERENT STRAINS OF MICE [J].
BANSINATH, M ;
RAMABADRAN, K ;
TURNDORF, H ;
PUIG, MM .
PHARMACOLOGY, 1991, 42 (02) :97-102
[2]
Fatty acid amide hydrolase controls mouse intestinal motility in vivo [J].
Capasso, R ;
Matias, I ;
Lutz, B ;
Borrelli, F ;
Capasso, F ;
Marsicano, G ;
Mascolo, N ;
Petrosino, S ;
Monory, K ;
Valenti, M ;
Di Marzo, V ;
Izzo, AA .
GASTROENTEROLOGY, 2005, 129 (03) :941-951
[3]
The hallucinogenic herb Salvia divinorum and its active ingredient salvinorin A inhibit enteric cholinergic transmission in the guinea-pig ileum [J].
Capasso, R ;
Borrelli, F ;
Capasso, F ;
Siebert, DJ ;
Stewart, DJ ;
Zjawiony, JK ;
Izzo, AA .
NEUROGASTROENTEROLOGY AND MOTILITY, 2006, 18 (01) :69-75
[4]
Inhibitory effect of palmitoylethanolamide on gastrointestinal motility in mice [J].
Capasso, R ;
Izzo, AA ;
Fezza, F ;
Pinto, A ;
Capasso, F ;
Mascolo, N ;
Di Marzo, V .
BRITISH JOURNAL OF PHARMACOLOGY, 2001, 134 (05) :945-950
[5]
Salvinorin A, an active component of the hallucinogenic sage Salvia divinorum is a highly efficacious κ-opioid receptor agonist:: Structural and functional considerations [J].
Chavkin, C ;
Sud, S ;
Jin, WZ ;
Stewart, J ;
Zjawiony, JK ;
Siebert, DJ ;
Toth, BA ;
Hufeisen, SJ ;
Roth, BL .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2004, 308 (03) :1197-1203
[6]
OPIOID INHIBITION OF SYNAPTIC TRANSMISSION IN THE GUINEA-PIG MYENTERIC PLEXUS [J].
CHERUBINI, E ;
MORITA, K ;
NORTH, RA .
BRITISH JOURNAL OF PHARMACOLOGY, 1985, 85 (04) :805-817
[7]
Hallucinogens: An update [J].
John H. Halpern .
Current Psychiatry Reports, 2003, 5 (5) :347-354
[8]
DETERMINATION OF RECEPTORS THAT MEDIATE OPIATE SIDE-EFFECTS IN THE MOUSE [J].
HAYES, AG ;
TYERS, MB .
BRITISH JOURNAL OF PHARMACOLOGY, 1983, 79 (03) :731-736
[9]
κ-Opioid receptor agonists modulate visceral nociception at a novel, peripheral site of action [J].
Joshi, SK ;
Su, X ;
Porreca, F ;
Gebhart, GF .
JOURNAL OF NEUROSCIENCE, 2000, 20 (15) :5874-5879
[10]
Hallucinogens [J].
Nichols, DE .
PHARMACOLOGY & THERAPEUTICS, 2004, 101 (02) :131-181